1401415-16-4

Upstream product

• 1203499-43-7 tert-butyl (3,4-dichloropyridin-2-yl)carbamate 
• 959578-03-1 3,4-dichloropyridine-2-carboxylic acid 
• 55934-00-4 3,4-dichloropyridine 
• 403-19-0 2-fluoro-4-nitrophenol 
• 1174046-97-9 3-chloro-N-(diphenylmethylene)pyridin-2-amine 
• 2402-77-9 2,3-dichloro-pyridine 
• 1174046-76-4 4-(4-amino-2-fluorophenoxy)-3-chloro-N-(diphenylmethylene)pyridin-2-amine 
• 1174046-75-3 3-chloro-N-(diphenylmethylene)-4-(2-fluoro-4-nitrophenoxy)pyridin-2-amine 
• 1174046-74-2 3-chloro-2-((diphenylmethylene)amino)pyridin-4(1H)-one 

Downstream Products

• 1415798-36-5 N-(4-(2-amino-3-chloropyridine-4-oxy)-3-fluorophenyl)-2-(dimethylamino)-4-(4-fluorophenyl)-5-oxo-4,5-dihydro-thiazolo[5,4-b]pyridine-6-formamide 
• 1415798-46-7 C₂₅H₁₇ClF₂N₆O₃ 
• 1025720-94-8 BMS-777607 

Relevant academic research and scientific papers

PHOSPHONATE CONJUGATES AND USES THEREOF

Phosphonate conjugates, preferably, bisphosphonate conjugates; methods of inhibiting Ron receptor tyrosine kinase and methods of treatment of bone destruction due to cancer or other conditions utilizing the provided phosphonate conjugates.

HETEROCYCLIC PYRIDONE COMPOUND, AND INTERMEDIATE, PREPARATION METHOD AND USE THEREOF

The present invention relates to a heterocyclic pyridone compound represented by General Formula (I), where the heterocyclic pyridone compound is used as a tyrosine kinase inhibitor, and particularly a c-Met inhibitor. The present invention also relates to intermediates for preparing heterocyclic pyridone compound and a preparation method. The present invention further relates to a pharmaceutical composition containing the heterocyclic pyridone compound as an active ingredient, and a use of the pharmaceutical composition in treatment of diseases associated with tyrosine kinase c-Met, especially cancer associated with c-Met, as a medicament.

The development of a scalable, chemoselective nitro reduction

We have demonstrated a scalable chemoselective reduction of a nitro functional group in the presence of an aryl imine using (NH4) 2S/EtOH or hydrogenation (Sponge Nickel) to afford the corresponding amino-imines in moderate to excellent yields. Other reducible groups such as aryl halides, styryl olefins, and ether linkages survived as well.